Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
2022-08-26 09:00:00
APRIL 1[st] - JUNE 30[th ](Previous year in brackets)
- Net sales amounted to TSEK 397 (TSEK 244).
- Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5).
- Earning per share before dilution at SEK -0,09 (SEK 0,13).
- Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280).
- Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
- Equity ratio was 43 % (87 %).
JANUARY 1[st] - JUNE 30[th ](Previous year in brackets)
- Net sales amounted to TSEK 705 (TSEK 302).
- Earnings before interest and taxes (EBIT) amounted to MSEK -11,1 (MSEK 2,2).
- Earning per share before dilution at SEK -0,16 (SEK 0,03).
- Cash flow from operating activities amounted to MSEK -12,7 (MSEK -12,1).
- Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
- Equity ratio was 43 % (87 %).
SUMMARY OF EVENTS DURING SECOND QUARTER
- AGM was held on May 19.
- RLS signs distribution agreement for the Middle East with the aim of commercializing ChloraSolv.
- RLS introduces ChloraSolv for the animal segment in Scandinavia. Distribution agreements are signed with Swevet for Denmark, Norway and Sweden.
- ChloraSolv is approved for leg ulcers in Kuwait.
SUMMARY OF EVENTS AFTER SECOND QUARTER
- The Journal of Wound Care publishes case studies regarding ChloraSolv from three British clinics.
- Björn Larsson takes over as CEO of RLS Global as of October 1, 2022.
The Interim Report Q2, 2022, is enclosed and is also available here (https://rls.global/wp-content/uploads/2022/08/RLS_Global_Q2_2022_EN.pdf).
PUBLICATION
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on August 26[th] 2022.